SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Hot Topics > Consolidation

Consolidation

Consolidation

The pharmaceutical industry seems besieged on all sides by declining R&D productivity, expiring patents and relentless downward pricing pressure. One effect of this onslaught has been an upsurge in the level of consolidation as industry players attempt to cut costs, expand research pipelines and lengthen geographic reach.

PCI Pharma Services' new owners focused on growth

02-Jun-2016 - Partners Group, a private markets investment manager, has agreed to acquire global pharmaceutical services provider PCI Pharma Services citing “trends towards outsourcing.”

Charles River: 2016 to be 'robust year'

11-May-2016 - After reporting a successful FY16, Charles River expects a successful new year driven by customer demand and enhanced strategic partnerships.

Aptuit bolsters its preclinical services with Exquiron acquisition

21-Apr-2016 - Aptuit has acquired Swiss CRO Exquiron Biotech, enhancing its drug identification and validation services.

ICIG completes acquisition of Sandoz site

04-Apr-2016 - International Chemical Investors Group (ICIG) has completed its acquisition of Sandoz Industrial Products GmbH from Novartis Group.

Amgen selects Patheon as a 'strategic' manufacturing partner

15-Mar-2016 - The flexible manufacturing deal with Amgen is a departure from the standard transactional contract approach, according to Patheon.

Crown Bioscience acquires PreClinOmics, adds CVMD models to portfolio

09-Mar-2016 - Crown Bioscience has announced the acquisition of PreClinOmics, an in vivo preclinical company specializing in early research in cardiovascular and metabolic diseases (CVMD).

Synexus buys US trial site network for patient access; follows recent deals by Icon, PRA and PPD

07-Mar-2016 - Synexus has bought trial site network Research Across America (RAA) in a deal it claims will give its customers access to the US market and additional study participants.

Generics consolidation continues: Mylan to acquire Meda for $9.9bn

16-Feb-2016 - The generic pharmaceuticals company, Mylan, has announced its offer to buy the Swedish specialty pharma company, Meda, in a deal valued at $9.9 bn.

Amatsigroup buys Q Biologicals in 'fragmented' EU bio-services space

27-Jan-2016 - French CDMO Amatsigroup will offer complete biologics development services and expand its European presence through the acquisition of Q Biologicals.

'Merger mania' could leave strategic CROs vulnerable in 2016, says PwC

05-Jan-2016 - Mergers among Big Pharma companies will continue into 2016 leaving strategic CRO partnerships at risk, according to a report from PwC.

Pfizer-Allergan deal: what next for contract manufacturers?

25-Nov-2015 - As CMOs wait to see the short-term fallout of the Pfizer-Allergan deal, an M&A expert says contract manufacturing will follow the CRO industry in embracing strategic alliances and consolidation....

CRL buys German mouse model CRO for €34m

24-Nov-2015 - Charles River has acquired German preclinical CRO Oncotest GmbH in a €34m ($36m) cash deal.

Recipharm reports 55% sales growth; North America next step in M&A strategy

05-Nov-2015 - Gaining a foothold in North America would complete Recipharm’s growth strategy in becoming a global CDMO leader, the firm says.

Video Q&A

Niche tech and biologics the new drivers for CMO consolidation, says PBOA

05-Nov-2015 - CMO consolidation strategy has shifted from building scale and adding geographies towards niche technologies and biologics, according to the founder of trade association PBOA.

'Highest ever' cancellation rate impairs Parexel's Q1 FY16 results

02-Nov-2015 - Parexel has lowered its revenue guidance for the year following cancellations worth $305m in its first quarter FY2016.

CROs engaging in a ‘war on talent’, Quintiles CEO says

30-Oct-2015 - The fight between CROs for clinical research associates (CRAs) and people with certain other skillsets is hotting up, with both Icon and Quintiles identifying it as an issue faced by...

Pfizer-Allergan megamerger report prompts speculation about fallout for CROs

29-Oct-2015 - Reports Pfizer is considering buying Allergan to create a company worth $330bn have once again raised fears of disruption for contract research organisations (CRO), although there are reasons to think...

Covance toxicology capacity use still suboptimal despite improvements

28-Oct-2015 - Covance has reported capacity use at its preclinical toxicology business is in the 70% range, meaning it is still well below optimal levels despite recent improvements.

CPhI Worldwide 2015

Rush to acquire ex-pharma sites means survival of the biggest for CMOs

22-Oct-2015 - As pharma sells off manufacturing capacity and outsources to large and specialist CMOs, smart contract houses will have an opportunity to grab market share in a currently fragmented sector, say...

Indian CMO latest acquisition in Recipharm's aggressive growth push

20-Oct-2015 - An agreement to buy Indian CMO Nitin boosts Recipharm’s presence in emerging markets and plays into its aggressive growth strategy, the firm says.

Greatbatch: $1.7bn acq 'transfromative' in the medical device space

22-Sep-2015 - Standard & Poor has assigned a ‘stable’ rating to Greatbatch after the contract manufacturer secured $1.5bn to buy fellow medical devicemaker Lake Region Medical.

Parexel: M&A likely to continue despite $200m stock repurchase plan

15-Sep-2015 - Parexel could repurchase up to $200m (€175m) of its stock in FY 2016, but one analyst says the firm remains committed to it M&A strategy.

Mid-size CRO consolidation: Chiltern completes Theorem deal

14-Sep-2015 - Chiltern has completed its acquisition of Theorem, making it the self-declared “largest mid-sized” CRO.

SynteractHCR: ‘Customers like working with a mid-sized CRO’

11-Sep-2015 - Tech investment, flexibility and responsiveness have led to double-digit growth in customers, mid-sized CRO SynteractHCR says.

Concept Life Sciences buys UK toxicology biz

18-Aug-2015 - British CRO Concept Life Sciences has bought toxicology business CXR Biosciences, its fourth acquisition since it formed in July 2014.

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...